# Structure Therapeutics Inc. (GPCR)

Source: https://www.quantisnow.com/company/GPCR
Generated: 2026-11-10T10:00:18.221Z

- Ticker: GPCR
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2023
- SEC CIK: 0001888886

## Latest GPCR news and filings

- 2026-11-09 21:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Structure Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-structure-therapeutics-inc-6781516)
- 2026-11-09 21:11 UTC [SEC Form 8-K] [Structure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/structure-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6781404)
- 2026-11-09 21:05 UTC [Earnings] [Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights](https://www.quantisnow.com/insight/structure-therapeutics-reports-third-quarter-2026-financial-results-and-recent-6781191)
- 2026-11-05 18:27 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-structure-therapeutics-inc-6775641)
- 2026-11-04 12:30 UTC [Conference Announcement] [Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference](https://www.quantisnow.com/insight/structure-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-6771348)
- 2026-10-19 20:13 UTC [Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026](https://www.quantisnow.com/insight/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026-6750615)
- 2026-09-22 21:59 UTC [SEC Form 4] [CHIEF MEDICAL OFFICER Coll Crespo Blas covered exercise/tax liability with 10,626 units of Ordinary Shares, decreasing direct ownership by 8% to 258,228 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/chief-medical-officer-coll-crespo-blas-covered-exercisetax-liability-with-6723339)
- 2026-09-08 12:09 UTC [SEC Form 8-K] [Structure Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/structure-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6707614)
- 2026-09-08 12:00 UTC [Earnings Date] [Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management](https://www.quantisnow.com/insight/structure-therapeutics-reports-positive-clinical-data-across-oral-small-molecule-6707526)
- 2026-09-03 11:30 UTC [Conference Announcement] [Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences](https://www.quantisnow.com/insight/structure-therapeutics-to-participate-in-upcoming-healthcare-investor-conferences-6704192)
- 2026-09-03 01:18 UTC [SEC Form 4] [CHIEF SCIENTIFIC OFFICER Lin Xichen exercised 17,817 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-lin-xichen-exercised-17817-units-of-ordinary-6703955)
- 2026-08-20 00:23 UTC [SEC Form 4] [CHIEF SCIENTIFIC OFFICER Lin Xichen exercised 11,817 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-lin-xichen-exercised-11817-units-of-ordinary-6689101)
- 2026-08-07 20:08 UTC [SEC Form 4] [Chief Commercial Officer Berrios John Joseph was granted 140,766 units of Ordinary Shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-berrios-john-joseph-was-granted-140766-units-6671535)
- 2026-08-07 20:06 UTC [SEC Form 3] [SEC Form 3 filed by new insider Berrios John Joseph](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-berrios-john-joseph-6671497)
- 2026-08-06 20:29 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Structure Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-structure-therapeutics-inc-6669508)
- 2026-08-06 20:13 UTC [SEC Form 8-K] [Structure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/structure-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6669182)
- 2026-08-06 20:05 UTC [Leadership Update] [Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights](https://www.quantisnow.com/insight/structure-therapeutics-reports-second-quarter-2026-financial-results-and-recent-6668754)
- 2026-08-06 14:41 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-structure-therapeutics-inc-6668138)
- 2026-08-05 20:49 UTC [SEC Form 4] [CHIEF SCIENTIFIC OFFICER Lin Xichen exercised 11,817 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-lin-xichen-exercised-11817-units-of-ordinary-6666048)
- 2026-07-24 13:11 UTC [SEC Form 4] [SEC Form 4 filed by See Remark 1 Fmr Llc](https://www.quantisnow.com/insight/sec-form-4-filed-by-see-remark-1-fmr-llc-6648049)
- 2026-07-15 22:57 UTC [SEC Form 4] [CHIEF SCIENTIFIC OFFICER Lin Xichen exercised 23,634 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-lin-xichen-exercised-23634-units-of-ordinary-6638691)
- 2026-06-30 00:32 UTC [SEC Form 4] [CHIEF SCIENTIFIC OFFICER Lin Xichen exercised 23,634 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-lin-xichen-exercised-23634-units-of-ordinary-6619656)
- 2026-06-18 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Russell Angus C.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-russell-angus-c-6609265)
- 2026-06-18 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Love Ted W](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-love-ted-w-6609257)
- 2026-06-18 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Waldstreicher Joanne](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-waldstreicher-joanne-6609256)
- 2026-06-18 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Dobmeier Eric](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-dobmeier-eric-6609254)
- 2026-06-18 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Tetlow Sharon](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-tetlow-sharon-6609252)
- 2026-06-18 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Welch Daniel G](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-welch-daniel-g-6609249)
- 2026-06-18 20:05 UTC [SEC Form 8-K] [Structure Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/structure-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6608566)
- 2026-06-05 20:05 UTC [Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity](https://www.quantisnow.com/insight/structure-therapeutics-announces-publication-in-nature-medicine-highlighting-phase-2b-6591106)
- 2026-05-26 20:05 UTC [Structure Therapeutics Announces Participation in Upcoming Investor Conferences](https://www.quantisnow.com/insight/structure-therapeutics-announces-participation-in-upcoming-investor-conferences-6572024)
- 2026-05-07 20:45 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Structure Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-structure-therapeutics-inc-6539998)
- 2026-05-07 20:42 UTC [SEC Form 8-K] [Structure Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/structure-therapeutics-inc-filed-sec-form-8-k-financial-statements-and-6539970)
- 2026-05-07 20:17 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Structure Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-structure-therapeutics-inc-6539455)
- 2026-05-07 20:05 UTC [Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights](https://www.quantisnow.com/insight/structure-therapeutics-reports-first-quarter-2026-financial-results-and-recent-6538755)
- 2026-04-27 20:05 UTC [Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions](https://www.quantisnow.com/insight/structure-therapeutics-to-present-aleniglipron-amylin-and-combination-data-at-6516239)
- 2026-04-27 12:37 UTC [Analyst Coverage Initiated] [Canaccord Genuity initiated coverage on Structure Therapeutics with a new price target](https://www.quantisnow.com/insight/canaccord-genuity-initiated-coverage-on-structure-therapeutics-with-a-new-6515771)
- 2026-04-23 20:30 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Structure Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-structure-therapeutics-inc-6512852)
- 2026-04-23 20:21 UTC [SEC Form 4] [COO & GC Lang Matthew was granted 184,614 units of Ordinary Shares (SEC Form 4)](https://www.quantisnow.com/insight/coo-gc-lang-matthew-was-granted-184614-units-of-ordinary-6512728)
- 2026-04-23 20:19 UTC [SEC Form 3] [SEC Form 3 filed by new insider Lang Matthew](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-lang-matthew-6512707)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/GPCR
- Earnings history: https://www.quantisnow.com/earnings/GPCR
- Dividend history: https://www.quantisnow.com/dividends/GPCR
- Insider transactions: https://www.quantisnow.com/insiders/GPCR
- Options chain: https://www.quantisnow.com/options/GPCR
- SEC 8-K filings only: https://www.quantisnow.com/company/GPCR/8-k
- RSS and alerts for GPCR: https://www.quantisnow.com/docs/rss-feeds.md